We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+39.69%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.16B
AUM Growth
+$655M
Cap. Flow
-$8.33M
Cap. Flow %
-0.26%
Top 10 Hldgs %
29.57%
Holding
149
New
12
Increased
35
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$68M
2
HUM icon
Humana
HUM
+$58.7M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$21.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$21M
5
APRE icon
Aprea Therapeutics
APRE
+$19.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$49M
2
ABBV icon
AbbVie
ABBV
+$39.8M
3
SYK icon
Stryker
SYK
+$38.7M
4
MDCO
Medicines Co
MDCO
+$32.8M
5
CI icon
Cigna
CI
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 90.33%
2 Consumer Staples 0.66%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
26
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$36.2M 1.14%
175,000
– –
ONC
27
BeOne Medicines Ltd
ONC
$39.4B
$35.6M 1.13%
214,800
– –
RARX
28
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$35.2M 1.11%
750,000
-85,000
-10% -$3.76M
CHRS icon
29
Coherus Oncology
CHRS
$196M
$35.1M 1.11%
1,950,000
+70,000
+4% +$1.29M
APRE icon
30
Aprea Therapeutics
APRE
$8.05M
$33.2M 1.05%
+36,200
New +$19.9M
NVRO
31
DELISTED
NEVRO CORP.
NVRO
$32.8M 1.04%
279,000
+36,500
+15% +$3.61M
COLL icon
32
Collegium Pharmaceutical
COLL
$956M
$32.4M 1.02%
1,575,000
-2,893
-0.2% -$48.2K
ACHC icon
33
Acadia Healthcare
ACHC
$2.94B
$32.4M 1.02%
975,000
-315,000
-24% -$9.87M
IDXX icon
34
Idexx Laboratories
IDXX
$46.2B
$31.4M 0.99%
120,200
– –
ALGN icon
35
Align Technology
ALGN
$12.3B
$30.9M 0.98%
110,900
– –
ASMB icon
36
Assembly Biosciences
ASMB
$529M
$30.7M 0.97%
125,000
+16,667
+15% +$3.07M
AGIO icon
37
Agios Pharmaceuticals
AGIO
$1.93B
$30.6M 0.97%
641,500
+289,000
+82% +$10.9M
BPMC
38
DELISTED
Blueprint Medicines
BPMC
$30.6M 0.97%
382,000
+48,500
+15% +$3.63M
MIRM icon
39
Mirum Pharmaceuticals
MIRM
$6.14B
$30.5M 0.96%
1,245,000
+454,952
+58% +$4.85M
AXNX
40
DELISTED
Axonics, Inc. Common Stock
AXNX
$30.5M 0.96%
1,100,000
+897,500
+443% +$21.4M
AMGN icon
41
Amgen
AMGN
$222B
$30.4M 0.96%
126,000
– –
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$2.55B
$29.9M 0.94%
700,000
+92,000
+15% +$3.8M
ASND icon
43
Ascendis Pharma A/S
ASND
$16.8B
$29.7M 0.94%
213,500
– –
QURE icon
44
uniQure
QURE
$3.22B
$28.7M 0.91%
400,000
+205,500
+106% +$11.3M
ACAD icon
45
Acadia Pharmaceuticals
ACAD
$5.03B
$28.7M 0.91%
670,000
+483,000
+258% +$21M
BMRN icon
46
BioMarin Pharmaceuticals
BMRN
$12.4B
$28.5M 0.9%
337,500
+195,000
+137% +$14.7M
SGEN
47
DELISTED
Seagen Inc. Common Stock
SGEN
$27.7M 0.87%
242,000
– –
TMO icon
48
Thermo Fisher Scientific
TMO
$220B
$26.3M 0.83%
81,000
– –
DCPH
49
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$26.3M 0.83%
421,890
+171,890
+69% +$8.17M
MDCO
50
DELISTED
Medicines Co
MDCO
$26.1M 0.83%
307,699
-492,301
-62% -$32.8M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rock Springs Capital Management held 149 positions worth $3.16B, up 26% from $2.51B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2019 filing shows 12 new, 35 increased, 32 reduced and 19 closed positions. Its largest new stake was Humana: 185,000 shares worth $67.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2019 buy was Humana: 185,000 shares worth $67.8M.
  • Rock Springs Capital Management added most to Johnson & Johnson in Q4 2019, an estimated $68M increase.
  • Rock Springs Capital Management's biggest Q4 2019 reduction was Medicines Co, cutting an estimated $32.8M.
  • Rock Springs Capital Management fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $3.16B portfolio in Q4 2019.
  • Rock Springs Capital Management opened 12 new positions and closed 19 in Q4 2019.
  • Rock Springs Capital Management's portfolio value rose 26% quarter-over-quarter to $3.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.